Abstract
BackgroundPancreatic cancer (PC) represents an unfavorable prognosis disease, even in patients with resectable disease. The aim of this series was to investigate the role of treatment intensification with adjuvant chemoradiation (CRT) in radically resected PC patients. MethodsData from PC patients undergone radical surgery, adjuvant chemotherapy (CT) and CRT throughout a 20-year period were retrospectively collected. Actuarial local control (LC) and the overall survival (OS) were the primary endpoints, while secondary end-points were the disease-free-survival (DFS) and metastases-free-survival (MFS). ResultsThe analysis included 108 PC patients treated with adjuvant CRT and CT from January 2000 to August 2019. Median age was 66 years (range: 40-83), all patients underwent radical surgical resection with adjuvant chemotherapy (88, 81,5%) plus concomitant chemoradiation (101, 93,5%) or radiotherapy alone (7, 6,5%). The median dose delivered on tumor bed was 50,4 Gy (range: 45-50,6 Gy), while median dose on regional lymphatic drainage stations was 39,6 Gy (range 39,6-45 Gy. Concomitant CT was gemcitabine-based regimen in the vast majority of patients (87, 80.6%). Median follow-up time was 21 months; the 2- and 5-years LC rate were 75,8% and 59,1%, respectively. Perineural invasion (PNI) at pathological assessment was found significantly associated to LC (p=0.028). Median OS was 40 months with 2- and 5-years OS rate of 73.9% and 41,6 % respectively.ConclusionsThe outcomes of this series strongly suggest that the impact of adjuvant CRT should be deeply investigated in PC patients. Timing, combination of modern CRT with new systemic therapies need to be further investigated to personalize therapy and optimize clinical advantages.